Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 3/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14149407 | 0.82 | BRD4 (0.41) | MAPK1BRD4CREBBPALDH1A1CYP1A2 | |
| SCHEMBL31332341 | 0.80 | SIGMAR1 (0.54) | ALDH1A1CYP2C19 | |
| SCHEMBL2849413 | 0.77 | MAOA (0.53) | MAPK1HPGDBRD4CREBBPCYP2D6 | |
| SCHEMBL4450850 | 0.75 | ALDH1A1 (0.34) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL13911356 | 0.74 | NPC1 (0.53) | BRD4CREBBPAHR | |
| SCHEMBL14433009 | 0.73 | MAPK1 (0.47) | MAPK1HPGDBRD4CREBBPALDH1A1 | |
| SCHEMBL682960 | 0.72 | ALDH1A1 (0.55) | HPGDALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL32082017 | 0.72 | ALDH1A1 (0.55) | HPGDALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL12533132 | 0.72 | MAPK1 (0.47) | MAPK1HPGDBRD4CREBBPALDH1A1 | |
| SCHEMBL7352717 | 0.72 | BRD4 (0.39) | MAPK1BRD4CREBBPALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148422-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20100160289-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160289-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM2, TRPM5 | MAPK1 1742/4885HPGD 3801/4885BRD4 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.